AbbVie (ABBV)
$173.15
0.46 (0.26%)
ABBV Stock Quote Delayed 30 Minutes
Exceptional Metrics for Sales Growth Keep AbbVie (ABBV) a Strong Buy at recent price of $116.34
AbbVie Inc's Strong Buy recommendation is the outcome of an analytical process that is proprietary and produced results that were above average in 5 areas: an economic sector rated above average in attractiveness, an industry group rated above average in attractiveness, a ranking in its sector group that is in the top decile, ranking in its industry group that is in the top decile, and a quantitative risk/reward calculation that is very attractive; and produced below average outcomes in 1 area: analytical scoring that is below average.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
2.93M
Day's Range
$172.77 - $174.59
52-Week Range
$135.85 - $182.89
Dividend & Yield
$5.92 (3.42%)
ABBV Stock Predictions, Articles, and AbbVie News
5 Biotech and Pharmaceutical Stocks Going Bonkers
These biotech and pharmaceutical stocks are soaring insanely high right now. Here's what investors should know about each of these hot stocks to buy.
AbbVie Inc Stock Soars on Strong Q4 Earnings Beat
AbbVie (ABBV) stock was flying high today following the release of a positive earnings report for the fourth quarter of 2017.
AbbVie Inc Dividend at Risk Amid Patent Protection Problems
ABBV remains a strong holding for dividend growth, but AbbVie is about to lose patent protection on Humira, which accounts for two-thirds of its revenue.
AbbVie (ABBV) a Strong Buy on Top-End Earnings Momentum
Portfolio Grader currently ranks AbbVie Inc (NYSE:ABBV) a Strong Buy. The methods for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. ABBV has maintained this ranking for the last month.
AbbVie (ABBV) a Strong Buy on Best-in-Class Quant Score
AbbVie Inc (NYSE:ABBV) is a constituent of the 350 company Biotechnology GICS industry group, which is a segment of the 782 company GICS Health Care sector. ABBV's market value is $153.7 billion which falls in the top decile in its industry group. The stock's current Portfolio Grader score places it 12 among the 350 companies in this industry group, positioning it among the leaders; among the sector leaders with a ranking of 40 among the 782 companies in the sector, and number 226 in the nearly 5,000 company Portfolio Grader universe.
Best-in-Class Quant Score Makes AbbVie (ABBV) a Strong Buy
AbbVie Inc (NYSE:ABBV) ranks in the top 10% of its industry group, Biotechnology, and in the top decile of sector group, Health Care, with a market value of $151.2 billion. From an investment attractiveness vantage point, ABBV is ranked among the sector leaders with a ranking of 38 among the 781 companies in the sector; the stock's current Portfolio Grader score places it 7 among the 349 companies in this industry group, putting it in the top decile and number 234 in the 5000 company Portfolio Grader company universe.
High-Level Measures for Earnings Momentum Keep AbbVie (ABBV) a Strong Buy
Currently, AbbVie Inc (NYSE:ABBV) has a Strong Buy using Louis Navellier's methodology for investing and his Portfolio Grader stock evaluator. ABBV has recently seen its Portfolio Grader rating upgraded from a Buy to a Strong Buy.
Earnings Momentum Analytics Power AbbVie (ABBV) to Strong Buy
The current recommendation of Strong Buy for AbbVie Inc (NYSE:ABBV) has been derived by using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. ABBV has been upgraded from a Buy to a Strong Buy in the last week.
AbbVie (ABBV) a Buy on Robust Quant Score
AbbVie Inc (NYSE:ABBV) is a $147.1 billion in market value member of the Biotechnology GICS industry group where the stock's current Portfolio Grader score places it 25 among the 349 companies in this industry group, putting it in the top decile. ABBV is ranked in the top quartile of the sector with a ranking of 96 among the 785 companies in the sector and number 621 in the 5000 company Portfolio Grader company universe.
AbbVie (ABBV) a Buy on Strong Quant Score
Currently, AbbVie Inc (NYSE:ABBV) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABBV has maintained this ranking for the last month.
AbbVie Inc (ABBV) Earnings: 12 Things to Know
AbbVie (ABBV) has released its earnings report for the third quarter of 2017 and 'InvestorPlace' has a few things to know about it.
Superior Earnings Momentum Keeps AbbVie (ABBV) a Buy
AbbVie Inc (NYSE:ABBV) is one of 345 companies within the Biotechnology GICS industry group, which is in turn part of the 782 company GICS Health Care sector. ABBV's market value is $153.2 billion which places it in the top decile in its industry group. The stock's current Portfolio Grader score places it 13 among the 345 companies in this industry group, putting it in the top decile; in the top decile of the sector with a ranking of 74 among the 782 companies in the sector, and number 626 in the nearly 5,000 company Portfolio Grader universe.
Catch This Falling Knife — Go Long Celgene Corporation
Pharma stock falling knives are the scariest to catch. But this reaction to the Celgene headline is overdone. Catch CELG but with caution.
AbbVie (ABBV) a Buy on Healthy Earnings Momentum
AbbVie Inc (NYSE:ABBV) is ranked as a Buy using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking ABBV has had from Portfolio Grader for the last month.
Hold Recommendation for AbbVie (ABBV) Stock Kept
Currently, AbbVie Inc (NYSE:ABBV) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. This represents no change from the previous week and is the same ranking ABBV has had from Portfolio Grader for 3 months.
